(firstQuint)Phase 1/2 Study of ARGX-110 in Patients With Advanced Malignancies.

 Phase I study conducted in patients whose tumors express the target of interest.

 PK, PD, biomarkers will be determined to support dose selection.

 Phase II study conducted in CTCL patients who are CD70 positive.

 PK, PD, biomarkers and IHC will be determined to assess efficacy.

 Phase 1/2 Study of ARGX-110 in Patients With Advanced Malignancies@highlight

The purpose of this study is to determine the recommended Phase 2 dose of ARGX-110, an antibody that binds CD70, in patients with advanced malignancies.

